Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Sacituzumab Tirumotecan + Tagitanlimab in PD-L1–Positive HR+/HER2- Advanced Breast Cancer After CDK4/6 Inhibitors
ChiCTR2600126018Phase 2Recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab tirumotecan and tagitanlimab in breast cancer, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-Free Survival Rate at 6 Months. Started Jun 2026; status: recruiting.
02
Drugs
sacituzumab tirumotecantagitanlimab
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2600126018.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126018.